BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs, choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer

被引：0

作者：

Kopetz, S. ^{[1
]}

Crothey, A. ^{[2
]}

Van Cutsem, E. ^{[3
]}

Yaeger, R. ^{[4
]}

Wasan, H. ^{[5
]}

Yoshino, T. ^{[6
]}

Desai, J. ^{[7
,8
]}

Ciardiello, F. ^{[9
]}

Gollerkeri, F. ^{[10
]}

Maharry, K. ^{[10
]}

Loupakis, F. ^{[11
]}

Hong, Y. ^{[12
]}

Steeghs, F. ^{[13
]}

Guren, T. ^{[14
]}

Arkenau, H. ^{[15
]}

Garcia Alfonso, P. ^{[16
]}

Sandor, V. ^{[17
]}

Christy-Bittel, J. ^{[10
]}

Anderson, L. ^{[18
]}

Tabernero, J. ^{[19
]}

机构：

[1] UT MD Anderson Canc Ctr, Houston, TX USA

[2] Mayo Clin, Rochester, MN USA

[3] UZ Leuven Campus Gasthuisberg, Leuven, Belgium

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Hammersmith Hosp, Dept Canc Med, London, England

[6] Natl Canc Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[7] Royal Melbourne Hosp, Parkville, Vic, Australia

[8] Walter & Eliza Hall Inst Med Res, Peter MacCallum Canc Ctr, Parkville, Vic, Australia

[9] Univ Campania L, Dipartimento Med Precis, Naples, Italy

[10] Array BioPharma Inc, Boulder, CO USA

[11] Veneto Inst Oncol IOV IRCCS, Med Oncol Unit 1, Clin & Expt Oncol Dept, Padua, Italy

[12] Asan Med Ctr, Seoul, South Korea

[13] Netherlands Canc Inst, Amsterdam, Netherlands

[14] Oslo Univ Hosp, Oslo, Norway

[15] HCA Healthcare, Sarah Cannon Res Inst, London, England

[16] Hosp Gen Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain

[17] Array BioPharma Inc, Cambridge, MA USA

[18] Array BioPharma, Boulder, CO USA

[19] VAll dHebron Univ Hosp, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA - 006

引用

页数：1

共 50 条

[1] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)
Tabernero, J.
Grothey, A.
Van Cutsem, E.
Yaeger, R.
Wasan, H.
Yoshino, T.
Desai, J.
Ciardiello, F.
Loupakis, F.
Hong, Y. Sang
Steeghs, N.
Guren, T. K.
Arkenau, H-T.
Garcia-Alfonso, P.
Gollerkeri, A.
Pickard, M.
Maharry, K.
Christy-Bittel, J. L.
Anderson, L.
Kopetz, S.
[J]. ANNALS OF ONCOLOGY, 2019, 30 : 868 - 868
[2] BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancer
Desai, Jayesh
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet
Yoshino, Takayuki
Ciardello, Fortunato
Gollerkeri, Ashwin
Maharry, Kati
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia Alfonso, Pilar
Price, Timothy
Strickland, Andrew
Tebbutt, Niall
Karapetis, Christos
Chantrill, Lorraine
Murphy, Felicity
Sandor, Victor
Christy-Bittel, Janna
Anderson, Lisa
Tabernero, Josep
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 99 - 99
[3] ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT BINIMETINIB FOR BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER: MANAGEMENT OF ADVERSE EVENTS FROM A RANDOMIZED, 3-ARM, PHASE 3 STUDY VS. THE CHOICE OF EITHER IRINOTECAN OR FOLFIRI PLUS CETUXIMAB (BEACON CRC)
Trevino, Tracy
Kopetz, Scott
Grothey, Axel
Yaeger, Rona
Sandor, Victor
Velez, Lydia
[J]. ONCOLOGY NURSING FORUM, 2020, 47 (02)
[4] BEACON: A Randomised, Phase 3 Study of Encorafenib and Cetuximab plus /- Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer Patients
Wasan, Harpreet
Arkenau, Tobias
Braun, Mike
Samuel, Leslie
Graham, Janet
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Yoshino, Takayuki
Desai, Jayesh
Ciardello, Fortunato
Gollerkeri, Ashwin
Maharry, Kati
Sandor, Victor
Christy-Bittel, Janna
Anderson, Lisa
Tabernero, Josep
[J]. BRITISH JOURNAL OF CANCER, 2019, 121 : 24 - 24
[5] Beacon Crc: a Randomized, Phase 3 Study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BiNI) vs. Choice of Either Irinotecan or Folfiri Plus Cetux in BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC)
Vogel, Arndt
Hegewisch-Becker, Susanna
Prager, Gerald
Folprecht, Gunnar
Stahl, Michael
Kopetz, Scott
Grothey, Axel
van Cutsetn, Eric
Yaeger, Rona
Wasan, Harpreet
Yoshino, Takayuki
Desai, Jayesh
Ciardello, Fortunato
Gollerkeri, Ashwin
Maharry, Kati
Loupakis, Fotios
Hong, Y.
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia-Alfons, Pilar
Sandor, Victor
Christy-Bittel, Farina
Anderson, Lisa
Tabernero, Josep
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 55 - 55
[6] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet Singh
Yoshino, Takayuki
Desai, Jayesh
Ciardiello, Fortunato
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia-Alfonso, Pilar
Gollerkeri, Ashwin
Maharry, Kati
Christy-Bittel, Janna
Keir, Christopher Hunt
Pickard, Michael D.
Tabernero, Josep
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[7] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet Singh
Yoshino, Takayuki
Desai, Jayesh
Ciardiello, Fortunato
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Kyrre Guren, Tormod
Arkenau, Hendrik-Tobias
Garcia-Alfonso, Pilar
Gollerkeri, Ashwin
Maharry, Kati
Christy-Bittel, Janna
Hunt Keir, Christopher
Pickard, Michael D.
Tabernero, Josep
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)
Price, Timothy
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet Singh
Yoshino, Takayuki
Desai, Jayesh
Ciardiello, Fortunato
Loupakis, Fotios
Hong, Yong S.
Steeghs, Neeltje
Guren, Tormod K.
Arkenau, Hendrik-Tobias
Garcia-Alfonso, Pilar
Chantrill, Lorraine
Tebbutt, Niall
Strickland, Andrew
Karapetis, Chris
Murphy, Felicity
Gollerkeri, Ashwin
Maharry, Kati
Christy-Bittel, Janna
Tabernero, Josep
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 128 - 128
[9] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
Wasan, Harpreet Singh
Yoshino, Takayuki
Desai, Jayesh
Ciardiello, Fortunato
Loupakis, Fotios
Hong, Yong Sang
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia-Alfonso, Pilar
Gollerkeri, Ashwin
Maharry, Kati
Christy-Bittel, Janna
Keir, Christopher Hunt
Pickard, Michael D.
Tabernero, Josep
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib plus cetuximab plus /- binimetinib in BEACON CRC
Aderka, D.
Kopetz, S.
Grothey, A.
Van Cutsem, E.
Yaeger, R.
Wasan, H.
Yoshino, T.
Desai, J.
Ciardiello, F.
Golden, A.
Edwards, M.
Tabernero, J.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S214 - S214

← 1 2 3 4 5 →